[Skip to Content]

Upstate Active Clinical Trials

Study Title:

A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

What is the purpose of the study?

To assess the impact on progression-free survival (PFS) with the addition of ixazomib and daratumumab to lenalidomide as a maintenance treatment after induction therapy with lenalidomide, ixazomib, dexamethasone, and daratumumab

Upstate Institutional Review Board (IRB) Number:

1846245

Study/Protocol ID:

AFT-41

Study Phase:

2

Patient Age Group:

Adults

Principal Investigator:

Krishna B Ghimire, MD

What is involved if I participate?

  • Is transportation provided or reimbursed?
    No
  • Is parking provided or reimbursed?
    No

Who can I contact for more information?

Name: Hardikkumar Panchal, MPA, MS
Phone: 315-464-8237
Email: panchalh@upstate.edu

Return to Previous Page || Search Again

Top